Evaluation of dyskerin expression and the Cajal body protein WRAP53β as potential prognostic markers for patients with primary vaginal carcinoma

Ranhem,Cecilia; Larsson,Gabriella Lillsunde; Lindquist,David; Sorbe,Bengt; Karlsson,Mats G.; Farnebo,Marianne; Hellman,Kristina; Kovalevska,Larysa; Kashuba,Elena; Andersson,Sonia

doi:10.3892/ol.2021.13148

Evaluation of dyskerin expression and the Cajal body protein WRAP53β as potential prognostic markers for patients with primary vaginal carcinoma

Authors:
- Cecilia Ranhem
- Gabriella Lillsunde Larsson
- David Lindquist
- Bengt Sorbe
- Mats G. Karlsson
- Marianne Farnebo
- Kristina Hellman
- Larysa Kovalevska
- Elena Kashuba
- Sonia Andersson
View Affiliations

Affiliations: Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden, School of Health and Medical Sciences, Örebro University, Campus USÖ, 701 82 Örebro, Sweden, Department of Radiation Sciences, Umeå Universitet, 901 87 Umeå, Sweden, Department of Oncology, Örebro University Hospital, 701 85 Örebro, Sweden, School of Medical Sciences, Örebro University, 701 85 Örebro, Sweden, Department of Bioscience and Nutrition, Karolinska Institutet, 141 83 Stockholm, Sweden, Department of Oncology‑Pathology, Karolinska Institutet, 171 64 Stockholm, Sweden, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine, 03022 Kiev, Ukraine
Published online on: November 23, 2021 https://doi.org/10.3892/ol.2021.13148
Article Number: 30
Copyright: © Ranhem et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary vaginal cancer (PVC) is a rare gynaecological malignancy, which, at present, lacks appropriate biomarkers for prognosis. The proteins dyskerin and WD repeat containing antisense to TP53 (WRAP53β), both of which exert their functions in the telomerase holoenzyme complex, have been shown to be upregulated in different cancer types. These proteins have also been proposed as prognostic markers in some types of cancer. The aim of the present study was to examine the expression patterns of dyskerin and WRAP53β in patients with PVC. Moreover, as part of a search for effective biomarkers to evaluate prognosis in PVC, the expression of these two proteins and their potential association with clinical variables and survival were also evaluated. The expression of dyskerin and WRAP53β was assessed in PVC tumour samples from 68 patients using immunohistochemistry. The majority of tumour samples showed low and moderate expression levels of dyskerin. Upregulation of dyskerin in tumour samples was significantly associated with a shorter survival time and a poorer cancer‑specific survival rate. WRAP53β was also expressed in most of the cells but was not significantly associated with clinical variables or survival. This study demonstrates that upregulation of dyskerin is significantly associated with poor prognosis. Thus, dyskerin may serve as a promising prognostic marker and a potential putative therapeutic target in PVC.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Hellman K, Silfversward C, Nilsson B, Hellstrom AC, Frankendal B and Pettersson F: Primary carcinoma of the vagina: factors influencing the age at diagnosis. The Radiumhemmet series 1956–96. Int J Gynecol Cancer. 14:491–501. 2004. View Article : Google Scholar : PubMed/NCBI
3	Hacker NF, Eifel PJ and van der Velden J: Cancer of the vagina. Int J Gynaecol Obstet. 131 (Suppl 2):S84–S87. 2015. View Article : Google Scholar : PubMed/NCBI
4	Ghezelayagh T, Rauh-Hain JA and Growdon WB: Comparing mortality of vaginal sarcoma, squamous cell carcinoma, and adenocarcinoma in the surveillance, epidemiology, and end results database. Obstet Gynecol. 125:1353–1361. 2015. View Article : Google Scholar : PubMed/NCBI
5	Hiniker SM, Roux A, Murphy JD, Harris JP, Tran PT, Kapp DS and Kidd EA: Primary squamous cell carcinoma of the vagina: Prognostic factors, treatment patterns, and outcomes. Gynecol Oncol. 131:380–385. 2013. View Article : Google Scholar : PubMed/NCBI
6	Shah CA, Goff BA, Lowe K, Peters WA III and Li CI: Factors affecting risk of mortality in women with vaginal cancer. Obstet Gynecol. 113:1038–1045. 2009. View Article : Google Scholar : PubMed/NCBI
7	Gadducci A, Fabrini MG, Lanfredini N and Sergiampietri C: Squamous cell carcinoma of the vagina: Natural history, treatment modalities and prognostic factors. Crit Rev Oncol Hematol. 93:211–224. 2015. View Article : Google Scholar : PubMed/NCBI
8	Hellman K, Lundell M, Silfversward C, Nilsson B, Hellstrom AC and Frankendal B: Clinical and histopathologic factors related to prognosis in primary squamous cell carcinoma of the vagina. Int J Gynecol Cancer. 16:1201–1211. 2006. View Article : Google Scholar : PubMed/NCBI
9	Larsson GL, Helenius G, Andersson S, Sorbe B and Karlsson MG: Prognostic impact of human papilloma virus (HPV) genotyping and HPV-16 subtyping in vaginal carcinoma. Gynecol Oncol. 129:406–411. 2013. View Article : Google Scholar : PubMed/NCBI
10	Hellman K, Lindquist D, Ranhem C, Wilander E and Andersson S: Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina. Br J Cancer. 110:1561–1570. 2014. View Article : Google Scholar : PubMed/NCBI
11	Hayflick L: The illusion of cell immortality. Br J Cancer. 83:841–846. 2000. View Article : Google Scholar : PubMed/NCBI
12	Blackburn EH: Switching and signaling at the telomere. Cell. 106:661–673. 2001. View Article : Google Scholar : PubMed/NCBI
13	Nguyen THD, Collins K and Nogales E: Telomerase structures and regulation: Shedding light on the chromosome end. Curr Opin Struct Biol. 55:185–193. 2019. View Article : Google Scholar : PubMed/NCBI
14	Venteicher AS, Abreu EB, Meng Z, McCann KE, Terns RM, Veenstra TD, Terns MP and Artandi SE: A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science. 323:644–648. 2009. View Article : Google Scholar : PubMed/NCBI
15	Mahmoudi S, Henriksson S, Weibrecht I, Smith S, Söderberg O, Strömblad S, Wiman KG and Farnebo M: WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodies. PLoS Biol. 8:e10005212010. View Article : Google Scholar : PubMed/NCBI
16	Montanaro L, Brigotti M, Clohessy J, Barbieri S, Ceccarelli C, Santini D, Taffurelli M, Calienni M, Teruya-Feldstein J, Trerè D, et al: Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J Pathol. 210:10–18. 2006. View Article : Google Scholar : PubMed/NCBI
17	Montanaro L, Calienni M, Bertoni S, Rocchi L, Sansone P, Storci G, Santini D, Ceccarelli C, Taffurelli M, Carnicelli D, et al: Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation. Cancer Res. 70:4767–4777. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zhang M, Pan Y, Jiang R, Hou P, Shan H, Chen F, Jiang T, Bai J and Zheng J: DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF-κB pathway. Oncol Rep. 40:968–978. 2018.PubMed/NCBI
19	Bellodi C, Krasnykh O, Haynes N, Theodoropoulou M, Peng G, Montanaro L and Ruggero D: Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res. 70:6026–6035. 2010. View Article : Google Scholar : PubMed/NCBI
20	Miao FA, Chu K, Chen HR, Zhang M, Shi PC, Bai J and You YP: Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion. Invest New Drugs. 37:1177–1186. 2019. View Article : Google Scholar : PubMed/NCBI
21	Liu B, Zhang J, Huang C and Liu H: Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis. PLoS One. 7:e431472012. View Article : Google Scholar : PubMed/NCBI
22	Penzo M, Ludovini V, Treré D, Siggillino A, Vannucci J, Bellezza G, Crinò L and Montanaro L: Dyskerin and TERC expression may condition survival in lung cancer patients. Oncotarget. 6:21755–21760. 2015. View Article : Google Scholar : PubMed/NCBI
23	O'Brien R, Tran SL, Maritz MF, Liu B, Kong CF, Purgato S, Yang C, Murray J, Russell AJ, Flemming CL, et al: MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin. Cancer Res. 76:3604–3617. 2016. View Article : Google Scholar : PubMed/NCBI
24	Mahmoudi S, Henriksson S, Corcoran M, Méndez-Vidal C, Wiman KG and Farnebo M: Wrap53, a natural p53 antisense transcript required for p53 induction upon DNA damage. Mol Cell. 33:462–471. 2009. View Article : Google Scholar : PubMed/NCBI
25	Henriksson S, Rassoolzadeh H, Hedström E, Coucoravas C, Julner A, Goldstein M, Imreh G, Zhivotovsky B, Kastan MB, Helleday T, et al: The scaffold protein WRAP53β orchestrates the ubiquitin response critical for DNA double-strand break repair. Genes Dev. 28:2726–2738. 2014. View Article : Google Scholar : PubMed/NCBI
26	Garvin S, Tiefenböck K, Farnebo L, Thunell LK, Farnebo M and Roberg K: Nuclear expression of WRAP53β is associated with a positive response to radiotherapy and improved overall survival in patients with head and neck squamous cell carcinoma. Oral Oncol. 51:24–30. 2015. View Article : Google Scholar : PubMed/NCBI
27	Silwal-Pandit L, Russnes H, Borgen E, Skarpeteig V, Moen Vollan HK, Schlichting E, Kåresen R, Naume B, Børresen-Dale AL, Farnebo M, et al: The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer. PLoS One. 10:e01399652015. View Article : Google Scholar : PubMed/NCBI
28	Hedström E, Pederiva C, Farnebo J, Nodin B, Jirström K, Brennan DJ and Farnebo M: Downregulation of the cancer susceptibility protein WRAP53β in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome. Cell Death Dis. 6:e18922015. View Article : Google Scholar : PubMed/NCBI
29	Bergstrand S, O'Brien EM and Farnebo M: The Cajal Body Protein WRAP53β Prepares the Scene for Repair of DNA Double-Strand Breaks by Regulating Local Ubiquitination. Front Mol Biosci. 6:512019. View Article : Google Scholar : PubMed/NCBI
30	Henriksson S and Farnebo M: On the road with WRAP53β: Guardian of Cajal bodies and genome integrity. Front Genet. 6:912015. View Article : Google Scholar : PubMed/NCBI
31	Zhang H, Wang DW, Adell G and Sun XF: WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients. BMC Cancer. 12:2942012. View Article : Google Scholar : PubMed/NCBI
32	Rao X and Huang D, Sui X, Liu G, Song X, Xie J and Huang D: Overexpression of WRAP53 is associated with development and progression of esophageal squamous cell carcinoma. PLoS One. 9:e916702014. View Article : Google Scholar : PubMed/NCBI
33	Zhu Y, Ding L, Chen BF, Song JG and Yao YS: Oncogenic Activity of Wrap53 in Human Colorectal Cancer In Vitro and in Nude Mouse Xenografts. Med Sci Monit. 24:6129–6136. 2018. View Article : Google Scholar : PubMed/NCBI
34	Herrington SC and Ordi J: Chapter 34: Tumours of the vagina. In: WHO Classification of Tumours: Female genital tumours. (5th edition). 4:WHO Classification of Tumours Editorial Board (ed), IARC Press. (Lyon, France). 2020.
35	Sieron P, Hader C, Hatina J, Engers R, Wlazlinski A, Müller M and Schulz WA: DKC1 overexpression associated with prostate cancer progression. Br J Cancer. 101:1410–1416. 2009. View Article : Google Scholar : PubMed/NCBI
36	Montanaro L, Calienni M, Ceccarelli C, Santini D, Taffurelli M, Pileri S, Treré D and Derenzini M: Relationship between dyskerin expression and telomerase activity in human breast cancer. Cell Oncol. 30:483–490. 2008.PubMed/NCBI
37	Bellodi C, McMahon M, Contreras A, Juliano D, Kopmar N, Nakamura T, Maltby D, Burlingame A, Savage SA, Shimamura A, et al: H/ACA small RNA dysfunctions in disease reveal key roles for noncoding RNA modifications in hematopoietic stem cell differentiation. Cell Rep. 3:1493–1502. 2013. View Article : Google Scholar : PubMed/NCBI
38	Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, Poustka A and Dokal I: X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet. 19:32–38. 1998. View Article : Google Scholar : PubMed/NCBI
39	Poncet D, Belleville A, t'kint de Roodenbeke C, Roborel de Climens A, Ben Simon E, Merle-Beral H, Callet-Bauchu E, Salles G, Sabatier L, Delic J, et al: Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood. 111:2388–2391. 2008. View Article : Google Scholar : PubMed/NCBI
40	Katzenellenbogen R: Telomerase Induction in HPV Infection and Oncogenesis. Viruses. 9:E1802017. View Article : Google Scholar
41	Klingelhutz AJ, Foster SA and McDougall JK: Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature. 380:79–82. 1996. View Article : Google Scholar : PubMed/NCBI
42	Koskimaa HM, Kurvinen K, Costa S, Syrjänen K and Syrjänen S: Molecular markers implicating early malignant events in cervical carcinogenesis. Cancer Epidemiol Biomarkers Prev. 19:2003–2012. 2010. View Article : Google Scholar : PubMed/NCBI